论文部分内容阅读
目的探讨血液滤过对重症疟疾的治疗效果。方法对12例接受血液滤过治疗的重症疟疾病例和20例未接受血液滤过治疗的重症疟疾病例的临床资料进行回顾性分析。结果血液滤过组平均住院时间为(19.2±3.5)d,明显少于对照组(25.3±4.2)d(P<0.05)。入ICU时血液滤过组的CRP、APACHE II评分和对照组相比差异无统计学意义(P>0.05);7d后血液滤过组CRP为(22.3±3.7)㎎/L,APACHE II评分为(8.5±2.3);对照组CRP为(46.3±5.7)㎎/L、APACHE II评分为(13.2±2.5),两组差异有统计学意义(P<0.05)。但在治愈率、非治愈率及受累器官分布方面两组差异无统计学意义。结论血液滤过对重症疟疾有辅助治疗作用。
Objective To investigate the therapeutic effect of hemofiltration on severe malaria. Methods The clinical data of 12 severe malaria cases receiving hemofiltration and 20 severe malaria cases without hemofiltration were retrospectively analyzed. Results The mean length of stay in hemodiafiltration group was (19.2 ± 3.5) d, which was significantly lower than that in control group (25.3 ± 4.2) d (P <0.05). There was no significant difference in CRP and APACHE II score between two groups (P> 0.05). After 7 days, CRP in hemofiltration group was (22.3 ± 3.7) ㎎ / L and APACHE II score was (8.5 ± 2.3). The CRP in the control group was (46.3 ± 5.7) ㎎ / L and the APACHE II score was (13.2 ± 2.5). There was significant difference between the two groups (P <0.05). However, in the cure rate, non-cure rate and distribution of affected organs, there was no significant difference between the two groups. Conclusion Hemofiltration is an adjuvant therapy for severe malaria.